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Abstract
Background: This study sought to evaluate the therapeutic effects of renal denervation (RDN) on acute myocardial
infarction (MI) in canines and explore its possible mechanisms of action.
Methods: Eighteen healthy mongrel dogs were randomly assigned to either the control group, the MI group or
the MI + RDN group. To assess cardiac function, left ventricular ejection fraction (LVEF), left ventricular end-diastolic
dimension (LVEDD), left ventricular end-systolic dimension (LVESD) and fraction shortening (FS) were recorded.
Additionally, haemodynamic parameters such as left ventricular systolic pressure (LVSP), left ventricular end-diastolic
pressure (LVEDP) and heart rate (HR) were measured. Cardiac oxidative stress levels were evaluated based on the
expression of p47phox mRNA, malondialdehyde (MDA), anti-superoxide anion free radical (ASAFR) and activity of
superoxide dismutase (SOD). To measure the local activity of the sympathetic nervous system (SNS) and
renin-angiotensin system (RAS), the levels of tyrosine hydroxylase (TH), angiotensin II (AngII), angiotensin-converting
enzyme 2 (ACE2), angiotensin (1–7) [Ang(1–7)] and Mas receptor (MasR) in myocardial tissues were recorded. The
expression of TH in renal tissue and serum creatinine were used to assess the effectiveness of the RDN procedure
and renal function, respectively.
Results: We found that MI deteriorated heart function and activated cardiac oxidative stress and the local
neurohumoral system, while RDN partially reversed these changes. Compared with the control group, parameters
including LVEDD, LVESD, LVEDP and the levels of ASAFR, MDA, p47phox,ACE2, Ang(1–7), MasR, AngII and TH-positive
nerves were increased (all P < 0.05) in myocardial infracted dogs; meanwhile, LVEF, FS, LVSP and SOD expression were
decreased (all P < 0.05). However, after RDN therapy, these changes were significantly improved (P < 0.05), except that
there were no significant differences observed in FS or LVSP between the two groups (P = 0.092 and 0.931,
respectively). Importantly, the expression of TH, AngII and Ang(1–7) was positively correlated with MDA and negatively
correlated with SOD. Between-group comparisons demonstrated no differences in serum creatinine (P = 0.706).
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Conclusions: RDN attenuated cardiac remodelling and improved heart function by decreasing the level of cardiac
oxidative stress and the local activity of the SNS and RAS in cardiac tissues. Additionally, the safety of the RDN
procedure was established, as no significant decrease in LVSP or rise in serum creatinine was observed in our study.
Keywords: Renal denervation, Acute myocardial infarction, Oxidative stress, Sympathetic nervous system, Renin-
angiotensin system
Background
The incidence of acute myocardial infarction (MI) has in-
creased over time. Chronic heart failure (CHF) is a com-
mon complication of acute MI, which places substantial
burden on the health care system. Complicated patho-
physiologic mechanisms participate in the development of
HF, among which the whole-body and local cardiac sym-
pathetic nervous system (SNS) and renin-angiotensin sys-
tem (RAS) contribute significantly to the pathogenesis of
CHF. Recently, oxidative stress has been demonstrated to
play a pivotal role in ventricular remodelling after MI. In
the clinical setting, drugs targeting these two systems,
such as angiotensin-converting enzyme inhibitors(ACEI),
angiotensin receptor blockers(ARB), mineralocorticoid re-
ceptor antagonists, and beta-blockers, have been the
mainstay of management for post-MI HF. Additionally,
anti-oxidative therapy has attracted increasing attention in
the cardiovascular field. However, despite intensive thera-
peutic treatment, a large number of patients continue to
experience worsening of HF symptoms. Thus, it remains
necessary to explore new therapeutic approaches for the
treatment of MI and its complications.
Previously published studies have shown that renal de-
nervation (RDN) provides significant benefits in delaying
the progression of cardiac hypertrophy [1], attenuating left
ventricular (LV) remodelling and improving cardiac func-
tion [2]. The activities of the systemic SNS and RAS [3, 4]
were shown to be decreased by RDN through interruption
of the renal sympathetic efferent and afferent nerves [5].
However, the effects of RDN on cardiac-specific SNS and
RAS activity and oxidative stress have not been investi-
gated. In the present study, we used an established canine
MI model to explore the related mechanisms, and thus
further validate that RDN could be used as a new treat-
ment for post-MI remodelling and HF.
Methods
Animals
Eighteen healthy mongrel dogs (male:female, 8:10),
weighing 15 ~ 18 kg, were used in this study (and were
provided by the Experimental Animal Centre in Tianjin).
The experiments were carried out in strict accordance
with the guide for the care and use of laboratory ani-
mals. The animals were kept under a 12/12-h light/dark
cycle and fed with regular chow and water ad libitum.
Experimental groups and conditions
All experimental mongrel canines were randomly di-
vided into three groups. (1) The control group (n = 6) re-
ceived only a coronary angiogram, followed by a renal
arteriogram one week later. (2) The MI group (n = 6)
underwent an established procedure inducing MI and,
one week later, underwent a renal arteriogram. (3) The
MI + RDN group (n = 6) underwent the MI-inducing
procedure, followed by renal denervation one week later.
Myocardial infarction
All animals were anesthetized with 6% sodium pentobar-
bital (30 mg/kg, intravenous (IV)), with an additional
50 mg given as needed through IV injection every 30 to
60 min, according to the reaction of the animals. The dogs
were placed on the operating table in a supine position.
Using a Mac-Lab (GE, United States) hemodynamic de-
tection system, electrocardiography (ECG) and vital signs
were monitored. The right iliac region was shaved and dis-
infected, and then a venous pathway was established. The
right femoral artery was punctured, and then a 6 F guiding
wire was inserted through the sheath, followed by the in-
jection of 1000 IU heparin. After verifying the coronary
anatomy, a bolus of gelatine sponge (1 mm in diameter)
was injected into the distal end of the fist diagonal branch
of the left anterior descending artery, as described previ-
ously [6]. Coronary angiography was performed again
10 min later to confirm interruption of the blood flow in
the distal vessels. The operation lasted 60–90 min.
Renal denervation
Under pentobarbital sodium (30 mg/kg, IV) anaesthesia,
bilateral renal denervation was performed in the MI +
RDN group; meanwhile, in the control and MI groups,
the operation was the same except that the nerves were
kept intact. The right femoral groin was shaved prior to
connecting the radio frequency ablation apparatus (IBI-
1500 T, IBI, United States). The temperature of the ra-
diofrequency ablation instrument was set at 43 °C, at a
power of 10 W, for a duration of 90 s. The right femoral
artery was punctured, and a 6 F guiding wire was
inserted through the guiding sheath. Renal angiography
was performed to determine the location of the renal ar-
tery. The ablation electrode (6 F ablation catheter tip,
electrode length of 4 mm) was then inserted, and radio
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frequency (RF) energy was applied to the endothelial lin-
ing. The catheter tip was placed in the proximal portion
of the renal artery main trunk, and the ablation proced-
ure was conducted by applying RF energy in the renal
artery distally to proximally and circumferentially. Then,
the catheter was withdrawn 1–2 cm to generate another
ablation location. Renal angiography was performed
again to validate that the catheter tip was well-attached
to the vessel wall before ablating at the new target site.
This procedure was repeated three to four times in the
renal artery, and then the same RF energy was applied to
the contralateral renal artery.
Transthoracic echocardiography
To evaluate LV function and cardiac chamber structure,
echocardiography was performed at baseline and 4 weeks
after MI (CX50, Philips, Netherlands). Parameters such
as the left ventricular ejection fraction (LVEF), left ven-
tricular end-diastolic dimension (LVEDD), left ventricu-
lar end-systolic dimension (LVESD) and fraction
shortening (FS) were recorded. LVEF was measured
using X-plane imaging and was calculated as follows:
(LVVmax- LVVmin)/LVVmax. Three consecutive car-
diac cycles were observed, and the average values were
recorded as the final cardiac parameters.
Detection of haemodynamics
Haemodynamic parameters were detected at baseline
and at 4 weeks post-MI. The right femoral artery was
punctured, and a 6 F pigtail catheter was used to
perform LV angiography. The heart rate (HR), left ven-
tricular systolic pressure (LVSP), and left ventricular
end-diastolic pressure (LVEDP) of each animal were
measured using the Mac-Lab system.
Enzyme-linked immunosorbent assay (ELISA)
The myocardial expression of AngII and Ang(1–7) were de-
tected using a commercial ELISA kit (Huamei Biological
Co., Wuhan, China). The reaction system and standard
curves were established according to the kit’s instructions.
Real-time reverse transcription polymerase chain reaction
(RT-PCR)
We used RT-PCR analysis to assay the mRNA expres-
sion of angiotensin-converting enzyme 2 (ACE2) and
MasR in the LV. Total RNA extraction was performed
according to the instructions provided with the Trizol
reagent (CWbio. Co. Ltd, Cat# CW0581). Template
cDNA was prepared from total RNA using the HiFi-
MMLV cDNA reverse transcription kit (CWbio. Co. Ltd,
Cat# CW0744). Quantitative PCR (Q-PCR), using an
ABI7500 (Applied Biosystems, United States), was per-
formed in triplicate for the amplification of target genes,
while GAPDH was selected as an endogenous control.
Each sample was run in duplicate with the following
thermocycler protocol: an initial step 95 °C for 10 min,
followed by 45 cycles at 95 °C for 15 s and 60 °C for
30 s. The PCR mix contained 0.4 uL (10 μmol) of for-
ward and reverse primers, 10 uL of 2× UltraSYBR Mix-
ture (CWbio. Co. Ltd, Cat# CW 0956), 2 uL of template
cDNA and RNase-free water to a final volume of 20 uL.
Melting curve analysis was used to confirm the specifi-
city and identify of the PCR products, and relative gene
expression changes were measured using the delta-delta
Ct method, where X = 2-ΔΔCt. The primer sequences
used are listed below in Table 1.
Immunohistochemistry analysis
Cardiac expression of TH was detected by immunohisto-
chemistry. Myocardial tissues were fixed with formalin,
and after embedding and dehydrating, the LV tissue was
sliced into 4-um sections. The sections were treated for
10 min with 1% methyl alcohol in H2O2 followed by
treatment with 0.01 M citrate buffer (pH 6.0) for 10 min
in a microwave oven, and the samples were then washed
with PBS after cooling to room temperature. The sec-
tions were incubated overnight at 4 °C with primary
antibody and again with biotinylated secondary antibody,
followed by the addition of streptavidin-conjugated
horseradish peroxidase. Immunohistochemistry staining
for TH was performed using the DAB staining system
according to the manufacturer’s instructions. Then, the
nuclei were counterstained with haematoxylin. Three
sections from each group were chosen for TH detection,
and the amount of TH was assessed in five randomly
chosen high-power fields from each sample. The investi-
gator was blinded to the specimen’s source. The raw
data were converted to an immunohistochemical score
(IHS) to show the immunoreactivity of TH-positive
nerves using an image analysis-based system [7].
Statistical analysis
Experimental data were analysed using SPSS version
20.00 software. Quantitative data are presented as the
Table 1 Specific primers for Q-PCR
Gene names Primers Product size
(bp)
ACE2 Forward: 5′- TTCAGCACAGTGGATCATCA-3′ 95
Reverse: 5′- CAAGTAATAAGCACTCCTGA-3′
MasR Forward: 5′- TGAGCAACAAGCTGAAGTCC-3′ 124
Reverse: 5′- AGGCACCTCCAGTCACACAA-3′
P47phox Forward: 5′- TGATTGCTGACTACAGCCAC-3′ 136
Reverse: 5′- AGGCTCCTCTGGTCCATCAA-3′
GAPDH Forward: 5′- CGGGCCGTCTTCCCCTCCAT-3′ 138
Reverse: 5′- CGGCCAGCCACGTCCAGACG-3′
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mean ± SD. Group comparisons were subjected to ana-
lysis of variance (ANOVA), followed by the Newman-
Keuls multiple comparison test to identify significant dif-
ferences between individual groups. P < 0.05 was consid-
ered statistically significant.
Results
One dog died due to a malignant arrhythmia on the 1st
day in the MI group, and one dog died on the 3rd day in
the MI + RDN group. There were no deaths in the
control group.
Baseline parameters
Dogs in each group were assessed for LVEDD, LVESD,
FS, LVEF, LVEDP, LVSP and HR before MI (shown in
Table 2) and there were no significant baseline differ-
ences between the three groups.
Cardiac function and haemodynamic parameters at
4 weeks post-MI
At 4 weeks post-MI, compared to the control group,
dogs from the MI and MI + RDN groups showed in-
creased LVEDD, LVESD and LVEDP, while the LVEF, FS
and LVSP values were all reduced. Importantly, com-
pared with the MI group, parameters such as LVEF,
LVEDD, LVESD and LVEDP were significantly improved
in the MI + RDN group, but no significant difference
was observed in FS and LVSP (P = 0.092 and P = 0.931,
respectively). Additionally, there were no significant dif-
ferences in HR among the three groups (shown in
Table 3).
Cardiac oxidative stress levels
As shown in Fig. 1, the cardiac infarct border zone was
obtained to assess oxidative stress levels. At 4 weeks
post-MI, the activities of MDA, p47phox, and ASAFR
were all increased compared to the control group, while
RDN treatment significantly reduced these changes
(shown in Fig. 1a-c). SOD activity in the control, MI,
and MI + RDN groups was 159.77 ± 11.90 U/mg prot,
105.14 ± 7.66 U/mg prot and 140.01 ± 14.10 U/mg prot,
respectively (shown in Fig. 1d).
Activity of the cardiac RAS
Compared with the control group, the expression of
AngII, ACE2, Ang(1–7) and MasR in myocardial tissue
was significantly increased in the MI and MI + RDN
groups. After intervention with RDN, the levels of AngII,
ACE2, Ang(1–7) and MasR were significantly decreased
in the RDN-treated group compared to the MI group
(shown in Fig. 2a-d).
Activity of the cardiac SNS
Four weeks post-MI, the relative expression of TH-
positive nerves in the myocardial tissue from the control,
MI and MI + RDN groups was 66.82 ± 13.09, 134.16 ±
12.06, and 101.14 ± 3.91, respectively. Compared with
the control group, the amount of TH-positive nerves
was markedly elevated in the MI and MI + RDN groups.
Importantly, a decrease in TH-positive nerves was seen
in the MI + RDN group compared with the MI group
(shown in Fig. 3a-b).
Correlation analysis
The expression of TH, AngII and Ang(1–7) was posi-
tively correlated with MDA (all P < 0.05) and negatively
correlated with SOD (all P < 0.05). The correlation
indexes are listed in Table 4.
TH-positive nerves in renal tissue
Four weeks after MI, the relative expression of TH-
positive nerves in renal tissue in the control, MI and MI
+ RDN groups was 93.44 ± 10.86, 102.26 ± 18.98, 75.69 ±
14.67, respectively. A decrease in TH-positive nerves
was seen in the MI + RDN group compared to the MI
group, while no significant difference (P = 0.071) was ob-
served between the control and MI + RDN groups
(shown in Fig. 4a-b).





MI + RDN group
(n = 6)
Weight (kg) 16.00 ± 1.27 16.67 ± 1.51 16.50 ± 1.05
LVEDD (cm) 3.01 ± 0.15 3.15 ± 0.14 3.07 ± 0.17
LVESD (cm) 1.99 ± 0.16 2.11 ± 0.12 2.12 ± 0.13
FS (%) 33.81 ± 3.76 33.12 ± 1.52 31.00 ± 3.37
LVEF (%) 55.80 ± 2.99 58.60 ± 3.72 58.05 ± 3.00
LVEDP (mmHg) 6.17 ± 2.79 5.33 ± 2.07 5.17 ± 1.60
LVSP (mmHg) 124.17 ± 7.06 123.67 ± 12.31 123.33 ± 9.99
HR (bpm) 78.33 ± 10.99 81.33 ± 18.11 76.33 ± 21.95
Baseline data are presented as the mean ± SD with no significant differences
between groups (all P > 0.05)
Table 3 Data for cardiac function and haemodynamic





MI + RDN group
(n = 5)
LVEDD (cm) 2.97 ± 0.15 3.75 ± 0.28* 3.40 ± 0.27*#
LVESD (cm) 1.96 ± 0.15 3.03 ± 0.16* 2.56 ± 0.16*#
FS (%) 34.03 ± 3.59 18.97 ± 6.32* 24.46 ± 4.26*
LVEF (%) 55.37 ± 2.98 37.04 ± 3.05* 41.72 ± 2.91*#
LVEDP (mmHg) 4.67 ± 1.63 16.00 ± 4.69*# 10.60 ± 3.05*#
LVSP (mmHg) 126.33 ± 13.29 104.60 ± 13.97* 103.80 ± 15.59*
HR (bpm) 80.50 ± 11.54 91.80 ± 32.95 74.40 ± 36.28
Values are presented as the mean ± SD
*P < 0.05 vs. control group; #P < 0.05 vs. MI group
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Comparison of serum creatinine at 4 weeks post-MI in
each group
The serum creatinine levels in the control, MI and
MI + RDN groups were 56.00 ± 19.12 μmol/L, 62.20
± 12.79 μmol/L and 64.80 ± 20.40 μmol/L, respect-
ively. No difference in serum creatinine among the
three groups was detected (P = 0.706, shown in
Fig. 5).
Discussion
Mounting evidence suggests that RDN is beneficial at
improving cardiac function in both experimental animals
and clinical patients. Hu et al. found that RDN was
superior to monotherapy with a beta blocker, ACEI or
ARB in decreasing plasma norepinephrine (NE) levels
and improving cardiac function in rats with MI [8]. A
significant improvement in diastolic function and a
Fig. 1 Cardiac oxidative stress levels in each group. a MDA, (b) p47phox subunit, (c) ASAFR, (d) SOD. * P < 0.05 vs. control group;# P < 0.05 vs.
MI group
Fig. 2 Detection of cardiac RAS activity. a AngII, (b) ACE2, (c) Ang(1–7), (d) MasR. The levels of AngII and Ang(1–7) were measured by ELISA. The
mRNA levels of ACE2 and MasR were detected through RT-PCR, and GAPDH was used as an internal control. * P < 0.05 vs. control group;
# P < 0.05 vs. MI group
Feng et al. BMC Cardiovascular Disorders  (2017) 17:65 Page 5 of 9
lowered LV mass index were also seen in RDN-treated re-
fractory hypertension patients [9]. The present study
showed that cardiac function was deteriorated after MI
and that RDN inhibited the process of ventricular remod-
elling and improved cardiac function. Acute MI results in
an increase in SNS and RAS activity in both the whole
body and local myocardial tissues, which is proportional
to the severity of post-MI HF [10, 11]. Additionally, react-
ive oxygen species (ROS), as the main effectors of oxida-
tive stress, play an important role in the ventricular
remodelling that occurs after MI [12]. Many studies have
shown that RDN is effective at reducing the whole-body
activity of the SNS and RAS. In our study, we explored
the effect of RDN on cardiac oxidative stress and local
activity of the SNS and RAS.
Previous studies have demonstrated that antioxidant
therapy distinctly inhibits oxidative stress, delays ven-
tricular remodelling and improves cardiac function after
MI [13, 14]. Oxidative stress results from imbalance of
the antioxidant and oxidant systems, which leads to
excessive ROS production. The biological effects of nico-
tinamide adenine dinucleotide phosphate (NADPH)
oxidase, one of the principle sources of ROS in the car-
diovascular system [15], are regulated by antioxidant en-
zymes such as SOD and catalase. The NADPH
p47phoxsubunit, composed of 390 amino acids, acts as a
connector between the components of the membrane
and cytoplasm and is essential for NADPH oxidase acti-
vation [16] and interstitial fibrosis [17]. MDA, the lipid
peroxidate product, is used as a measure of the body’s
oxidative levels. SOD is a vital antioxidant enzyme and
effectively clears free oxygen radicals. In our study, we
found that RDN reduced the high level of oxidative
stress after MI. In addition, the activity of ASAFR in
dogs from the MI + RDN group was lower than in those
from the MI group. Regarding this phenomenon, we
propose that RDN reduces the myocardial oxidative level
mainly through decreasing the generation of superoxide
rather than increasing the activity of ASAFR, which
clears superoxide production.
It is well known that chronic sustained sympathetic
over-activity results in the aggravation and deterioration
of HF. Previously published studies have shown that
RDN can reduce HR, NE overflow and muscle SNS ac-
tivity [18–20]; meanwhile, RDN has also demonstrated
beneficial effects in various conditions with high SNS ac-
tivity, such as resistant hypertension, HF, malignant
arrhythmia, impaired glucose tolerance and chronic
renal dysfunction [1, 21–23]. Research has further dem-
onstrated that TH-positive nerves can be used as an
b
a
Fig. 3 a TH immunohistochemical staining at the infarct border zone of nerve fibres (×400). Compared with the control group, the TH nerve fibres in
the MI and MI + RDN groups were increased. However, after treatment with RDN, the quantity of TH nerve fibres was significantly decreased, and an
orderly appearance of fibres was observed. b Expression of TH-positive nerves in cardiac tissues. * P < 0.05 vs. control group;# P < 0.05 vs. MI group
Table 4 Correlation analysis
TH (IHS) AngII (pg/mL) Ang(1–7) (pg/mL)
MDA (nmol/mg prot) 0.900 0.876 0.832
SOD (nmol/mg prot) −0.818 −0.674 −0.806
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indirect indicator of sympathetic activity [24]. In our re-
search, the effectiveness of removing sympathetic nerve
activity by RDN was demonstrated by the decrease in
TH-positive fibres in renal tissues. Moreover, the relative
expression of TH nerve fibres, which reflects the local
activity of the SNS, was also down-regulated in cardiac
tissue, suggesting that RDN lowered the over-activation
of the SNS in myocardial tissues.
The RAS is also a crucial mediator of myocardial fibro-
sis, pathological hypertrophy and HF [25, 26]. The adverse
effects of the RAS on cardiovascular disease are mainly
due to increased AngII, which exerts its effects through
the classical ACE-AngII-AT1R axis. Importantly, the
ACE2-Ang(1–7)-MasR axis, known as an endogenous
counter-regulator of the RAS, has been confirmed to be
protective in CHF [27]. The development of cardiovascu-
lar disease has been found to involve to both axes of the
RAS [28]. ACE2’s major biological function is converting
AngII into Ang(1–7), which is the physiological antagonist
of AngII [29–31]. Ang(1–7) exerts vasodilatory, anti-
proliferative, anti-inflammatory, and protective effects
through activation of MasR. Previous studies have shown
that ACE2 is increased in MI or HF [32–35]. As reported
previously, the ACE2 gene was upregulated in HF patients
and was associated with the degree of LVEDD and LVEF
loss [36]. In agreement with previous investigations, our
study showed that AngII and the compensatory ACE2-
Ang(1–7)-MasR axis were increased in MI dogs, although
these changes were reversed by ablation of renal sympa-
thetic nerves. The exact mechanisms for the decreased ex-
pression of ACE2-Ang(1–7)-MasR after RDN are not fully
understood; we speculate that RDN effectively inhibits LV
dilatation and modifies cardiac function by reducing the
activation of AngII to a significantly higher degree, which
in turn leads to a relatively weakened compensatory
mechanism. Importantly, a previous study reported that
the enhanced ACE2 and Ang(1–7) levels were significantly
a
b
Fig. 4 a TH immunohistochemical staining of nerve fibres in renal tissue (×400). Compared with the MI group, the density of TH nerve fibres was
decreased in the MI + RDN group; no difference was observed between the control and MI + RDN groups. b Expression of TH-positive nerves in
renal tissues. # P < 0.05 vs. MI group
Fig. 5 Serum creatinine levels at 4 weeks post-MI in each group. No
differences were observed in serum creatinine among the
three groups
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reduced after treatment with Telmisartan in rats with HF
[32], which is consistent with our results.
Cardiac SNS, RAS and oxidative stress mutually influ-
ence each other. AngII-induced phosphorylation of
p47phox [16] and myocardial hypertrophy induced by
ROS mediate various signalling pathways [37]. Moreover,
the AngII type 1 receptor (AT1R) blocker irbesartan and
Ang(1–7) blocked NADPH oxidase activation and thus
restored systolic function and carotid flow in an animal
study [38, 39]. Other studies have shown that ROS in-
crease SNS activity both in the central and peripheral
nervous systems [40]. In our study, we found that RDN
lowered the expression of AngII, MDA and TH-positive
nerve fibres in the heart, and the change in MDA was
positively correlated with AngII and TH. Our prelimin-
arily hypothesis is that RDN improves cardiac function
by reducing the activity of the cardiac AngII-ROS-SNS
axis, which needs to be confirmed in future research.
Safety issues related to the procedure for RDN have
attracted great attention. The REACH Pilot study evalu-
ated the safety of RDN for HF, and no significant reduc-
tion in blood pressure or other haemodynamic
disturbances were observed [1]. Mahfound et al. found
that RDN reduced the renal resistance index without de-
creasing the glomerular filtration rate (GFR), and no
renal artery stenosis or dissection was recorded [41]. He-
ring et al. demonstrated that RDN had no negative influ-
ence on patients with renal insufficiency [23]. In the
present study, the LVSP and serum creatinine level
showed no significant difference after RDN compared
with the non-RDN treated group, thereby demonstrating
the short-term safety of the RDN procedure.
Conclusion
RDN exerts a protective effect against acute MI, which
may be attributed to antioxidant effects and a decrease
in the local activity of the SNS and RAS. In conclusion,
RDN may serve as a new therapeutic treatment for MI
patients by blocking these adverse mechanisms.
Limitations
With regard to our study, some limitations should be
considered. First, myocardial infarction was only vali-
dated by the pathological specimen and echocardiog-
raphy, and we did not evaluate the infarct size, which
reduces the persuasion to a certain extent. Second, the
number of subjects was not large enough, which may
have affected our statistical analysis. Third, due to lack
of a control + RDN group, the effects of the intervention
could not be excluded completely. Finally, the observa-
tion time was short. To confirm the validity of these
results, studies both in humans and animals should be
undertaken on a larger scale and with a longer observa-
tion time.
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